theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Ophthalmology

ASCO Journal Club   

Journal Club Q&A done in partnership with ASCO the Journal of Clinical Oncology

Questions discussed in this category


What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
2 Answers available
24332


Papers discussed in this category


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 12
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Related Topics in Ophthalmology

  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers
  • Melanoma/Skin Cancer

Copyright © 2025 theMednet
All Rights Reserved.